600
Participants
Start Date
March 31, 2015
Primary Completion Date
July 31, 2025
Study Completion Date
July 31, 2025
Sirolimus
Sirolimus treatment will be part of a participant's clinical care and will be managed by their physician.
Everolimus
Everolimus treatment will be part of a participant's clinical care and will be managed by their physician.
ACTIVE_NOT_RECRUITING
University of Pennsylvania Medical Center, Philadelphia
ACTIVE_NOT_RECRUITING
Medical University of South Carolina, Charleston
RECRUITING
Mayo Clinic Jacksonville, Jacksonville
RECRUITING
Emory University School of Medicine, Atlanta
ACTIVE_NOT_RECRUITING
Cleveland Clinic, Cleveland
ACTIVE_NOT_RECRUITING
University of Cincinnati, Cincinnati
RECRUITING
University of Michigan, Ann Arbor
ACTIVE_NOT_RECRUITING
Mayo Clinic Rochester, Rochester
ACTIVE_NOT_RECRUITING
Loyola University Medical Center, Chicago, Maywood
RECRUITING
Washington University School of Medicine, St Louis
ACTIVE_NOT_RECRUITING
University of Texas Southwestern Medical Center, Dallas
ACTIVE_NOT_RECRUITING
University of Texas Health Center, Houston
RECRUITING
National Jewish Health, Denver
ACTIVE_NOT_RECRUITING
University of Utah School of Medicine, Salt Lake City
RECRUITING
Stanford University Medical Center, Stanford
ACTIVE_NOT_RECRUITING
Oregon Health and Science University, Portland
ACTIVE_NOT_RECRUITING
Swedish Medical Center, Seattle
RECRUITING
Brigham and Women's Hospital, Boston
RECRUITING
University of Rochester Medical Center, Rochester
ACTIVE_NOT_RECRUITING
Vanderbilt University Medical Center, Nashville
Rare Diseases Clinical Research Network
NETWORK
National Institutes of Health (NIH)
NIH
National Heart, Lung, and Blood Institute (NHLBI)
NIH
The LAM Foundation
OTHER
University of Cincinnati
OTHER